

QCDR Measure:

AAO-17: Acute Anterior Uveitis: Post-treatment Grade O anterior chamber cells

National Quality Strategy Domain:

Effective Clinical Care

Measure Type:

Outcome

Description:

Percentage of patients with acute anterior uveitis post-treatment with Grade O anterior chamber cells

Instructions:

This measure is to be reported a minimum of <u>once per reporting period</u> for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with acute anterior uveitis (in either one or both eyes) will submit this measure.

Denominator:

Patients aged 18 years or older who underwent treatment for acute anterior uveitis

Denominator Criteria

Patients aged ≥ 18 years

AND

Diagnosis of Acute Uveitis

- Unspecified acute and subacute iridocyclitis (ICD-10: H20.00)
- Primary iridocyclitis (ICD-10: H20.011, H20.012, H20.013, H20.019)
- Recurrent acute iridocyclitis (ICD-10: H20.021, H20.022, H20.023, H20.029)

AND

Treatment for Acute Uveitis which includes topical corticosteroids and antimicrobial/antivirals for infectious cases.

Numerator:

Patients with Grade 0 anterior chamber cells at 30 days after onset of treatment and not on topical corticosteroids at 60 days after treatment.

Numerator Options:

Performance Met: Patients achieved Grade 0 anterior chamber cells at 30

days after onset of treatment.

AND

Patient was not taking topical corticosteroids at 60 days

after onset of treatment

Performance Not Met: Patients who did not achieve Grade 0 anterior chamber

cells at 30 days after onset of treatment.

Grading Scheme for Anterior Chamber Cells

Grade	Cells in Field*
0	<1
0.5+	1-5
1+	6-15
2+	16-25
3+	26-50
4+	>50

^{*} Field size is a 1 mm by 1 mm slit beam.

Reference: Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. American Journal of Ophthalmology, Volume 140, Issue 3, 509 - 516

Improvement Notation:

Higher score indicates better performance